In a comprehensive analysis of 1154 early stage CLL seen at 4 European centres,33 CD38+ was predictive of a shorter TTFT (median 9.3 years vs not reached) and shorter survival (median 14,7 years) by multivariable analysis (Table 1). This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.